Author
Listed:
- Ahmad Altiti
(Feinstein Institutes for Medical Research, Northwell Health)
- Mingzhu He
(Feinstein Institutes for Medical Research, Northwell Health)
- Sonya VanPatten
(Feinstein Institutes for Medical Research, Northwell Health)
- Kai Fan Cheng
(Feinstein Institutes for Medical Research, Northwell Health)
- Umair Ahmed
(Feinstein Institutes for Medical Research, Northwell Health)
- Pui Yan Chiu
(Feinstein Institutes for Medical Research)
- Ibrahim T. Mughrabi
(Feinstein Institutes for Medical Research, Northwell Health)
- Bayan Al Jabari
(Feinstein Institutes for Medical Research, Northwell Health)
- Ronald M. Burch
(Applied Immunotherapeutics, Inc)
- Kirk R. Manogue
(Feinstein Institutes for Medical Research)
- Kevin J. Tracey
(Feinstein Institutes for Medical Research, Northwell Health)
- Betty Diamond
(Feinstein Institutes for Medical Research)
- Christine N. Metz
(Feinstein Institutes for Medical Research
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell)
- Huan Yang
(Feinstein Institutes for Medical Research, Northwell Health)
- LaQueta K. Hudson
(Donald and Barbara Zucker School of Medicine at Hofstra/Northwell)
- Stavros Zanos
(Feinstein Institutes for Medical Research, Northwell Health)
- Myoungsun Son
(Feinstein Institutes for Medical Research)
- Barbara Sherry
(Feinstein Institutes for Medical Research)
- Thomas R. Coleman
(Feinstein Institutes for Medical Research)
- Yousef Al-Abed
(Feinstein Institutes for Medical Research, Northwell Health
Feinstein Institutes for Medical Research)
Abstract
Peptides, polymers of amino acids, comprise a vital and expanding therapeutic approach. Their rapid degradation by proteases, however, represents a major limitation to their therapeutic utility and chemical modifications to native peptides have been employed to mitigate this weakness. Herein, we describe functionalized thiocarbazate scaffolds as precursors of aza-amino acids, that, upon activation, can be integrated in a peptide sequence to generate azapeptides using conventional peptide synthetic methods. This methodology facilitates peptide editing—replacing targeted amino acid(s) with aza-amino acid(s) within a peptide—to form azapeptides with preferred therapeutic characteristics (extending half-life/bioavailability, while at the same time typically preserving structural features and biological activities). We demonstrate the convenience of this azapeptide synthesis platform in two well-studied peptides with short half-lives: FSSE/P5779, a tetrapeptide inhibitor of HMGB1/MD-2/TLR4 complex formation, and bradykinin, a nine-residue vasoactive peptide. This bench-stable thiocarbazate platform offers a robust and universal approach to optimize peptide-based therapeutics.
Suggested Citation
Ahmad Altiti & Mingzhu He & Sonya VanPatten & Kai Fan Cheng & Umair Ahmed & Pui Yan Chiu & Ibrahim T. Mughrabi & Bayan Al Jabari & Ronald M. Burch & Kirk R. Manogue & Kevin J. Tracey & Betty Diamond &, 2022.
"Thiocarbazate building blocks enable the construction of azapeptides for rapid development of therapeutic candidates,"
Nature Communications, Nature, vol. 13(1), pages 1-13, December.
Handle:
RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-34712-9
DOI: 10.1038/s41467-022-34712-9
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-34712-9. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.